Oorja Bio Inc. secured $30 million in a Series A round from founding investor Westlake Biopartners to advance its in-licensing approach for idiopathic pulmonary fibrosis (IPF) and related fibrotic and cardiopulmonary diseases. The funding is positioned to support translational development decisions across target selection, preclinical package building, and progression toward mid-stage clinical studies. The financing also reflects ongoing investor appetite for fibrotic disease platforms as IPF remains an area with high unmet need and expensive chronic care burden.